10-K: GT Biopharma Faces Going Concern Doubt Amid Rising Losses

GT Biopharma, a clinical-stage biopharmaceutical company, reported a significant net loss and substantial doubt about its ability to continue as a going concern, despite advancing its TriKE product pipeline.

Summary

• GT Biopharma is a clinical-stage biopharmaceutical company focused on developing novel immuno-oncology products using its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.
• The company's TriKE platforms are designed to harness and enhance the cancer-killing abilities of a patient's natural killer (NK) cells.
• Clinical development for GTB-3550 was suspended to focus resources on more potent second-generation camelid nanobody TriKEs.
• The FDA cleared the Investigational New Drug (IND) application for GTB-3650 (targeting CD33 for relapsed/refractory AML and high-risk MDS) in late June 2024, with study enrollment commencing on January 21, 2025.
• The FDA cleared the IND application for GTB-5550 (a B7-H3 targeted TriKE for advanced solid tumors) in early January 2026, with study enrollment anticipated to begin mid-2026.
• GTB-7550, a TriKE for lupus and other autoimmune disorders, is currently in development, and the company is exploring potential manufacturers.
• The company reported a net loss of approximately $28.4 million for the year ended December 31, 2025, a significant increase from $13.2 million in 2024.
• Cash used in operations amounted to approximately $12.9 million for the year ended December 31, 2025.
• As of December 31, 2025, cash and cash equivalents and restricted cash totaled approximately $6.9 million, and working capital was approximately $5.8 million.
• Both management and the independent registered public accounting firm have raised substantial doubt about the company's ability to continue as a going concern.
• On November 20, 2025, the company received a Nasdaq notice for non-compliance with the $1 minimum bid price requirement, with a compliance period until May 19, 2026.
• The company restated its previously issued interim financial statements for the quarters ended June 30, 2025, and September 30, 2025, due to a material weakness in internal control over financial reporting related to the accounting for complex financial transactions (Greenshoe Rights liability).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with significant caution due to the substantial increase in net loss, explicit going concern doubt from both management and auditors, and the Nasdaq delisting risk, despite some progress in clinical development. The financial instability overshadows the pipeline advancements.

Positives

• The FDA cleared the IND application for GTB-3650 in late June 2024, allowing study enrollment to begin on January 21, 2025, for relapsed/refractory AML and high-risk MDS.
• The FDA cleared the IND application for GTB-5550 in early January 2026, with study enrollment for B7-H3+ solid tumors anticipated mid-2026.
• Preclinical data for GTB-3650 demonstrated markedly enhanced potency compared to the first-generation GTB-3550, providing a strong rationale for advancing the camelid-based platform.
• Preclinical work for GTB-5550 has shown NK-cell targeted activity against a variety of solid tumors, including head and neck, prostate, breast, ovarian, glioblastoma, and lung cancer.
• The company regained compliance with Nasdaq's Minimum Stockholders Equity Requirement by June 13, 2025.
• A legal services firm agreed to reduce the company's prior year unpaid fees by approximately $1 million in June 2025, resulting in a gain on settlement of vendor payable.
• Total cash and cash equivalents and restricted cash increased to $6.9 million as of December 31, 2025, from $4.0 million in 2024.
• Working capital improved significantly to $5.8 million as of December 31, 2025, from a deficit of $1.7 million in 2024.

Negatives

• Net loss increased by 115% to approximately $28.4 million for the year ended December 31, 2025, compared to $13.2 million in the prior year.
• Both management and the independent registered public accounting firm have raised substantial doubt about the company's ability to continue as a going concern.
• The company has a history of operating losses and expects to continue incurring significant losses for the foreseeable future, with no product sales or royalty revenues generated to date.
• Received a Nasdaq non-compliance notice on November 20, 2025, for failing to meet the $1 minimum bid price requirement, with a compliance deadline of May 19, 2026.
• Interim financial statements for the quarters ended June 30, 2025, and September 30, 2025, were restated due to a material weakness in internal control over financial reporting related to the accounting for complex financial transactions.
• The company will need additional capital to fund its operations and product development, and its ability to obtain necessary financing on acceptable terms is uncertain.
• Future equity financings, including through the Committed Equity Facility, could result in significant dilution to existing stockholders.
• The company faces ongoing legal proceedings with its former CFO and convertible noteholders, which could be costly and divert management's attention.

Risks

• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The business is at an early stage of development, and there is no assurance that therapeutic products can be successfully developed and commercialized.
• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future, potentially never generating revenue or achieving profitability.
• Additional capital is needed to conduct operations and develop products, and the ability to obtain necessary funding is uncertain.
• Research and development costs could exceed projections, potentially requiring significant modification of planned operations.
• Limited clinical testing and regulatory capabilities, coupled with the expensive, time-consuming, and difficult nature of human clinical trials, may lead to product failure or delays.
• Delays or difficulties in patient enrollment for clinical trials could prolong development and hinder regulatory approvals.
• Extensive and costly regulatory requirements may lead to unanticipated delays, and even approved products may face ongoing regulatory difficulties.
• The company's intellectual property may be compromised, and efforts to protect proprietary technologies may be inadequate, harming its competitive position.
• Claims of infringing the intellectual property rights of others may prevent or delay drug discovery and development efforts.
• The company may need or be forced to seek additional licenses for third-party intellectual property, which may not be available on commercially reasonable terms or at all.
• Failure to meet obligations under license agreements could result in the loss of rights to key technologies.
• Reliance on non-employee consultants, research institutions, and scientific contractors, whose activities are not wholly within the company's control, may lead to development delays.
• Business practices are subject to scrutiny and potential investigation by regulatory and government enforcement authorities, as well as private lawsuits, potentially leading to adverse consequences.
• Failure to comply with U.S. healthcare laws could result in substantial penalties and financial exposure.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-marketing.
• Limited resources may be expended on product candidates or indications that do not become commercially viable, potentially missing more profitable opportunities.
• Products may be expensive to manufacture, and profitability could be impacted if manufacturing costs are not controlled.
• Lack of commercial-scale manufacturing capabilities and an alternate manufacturing supply could negatively impact the ability to meet future product demand.
• The business is based on novel technologies that are inherently expensive and risky and may not be understood or accepted in the marketplace.
• Potential for product liability lawsuits based on the use of product candidates in clinical testing or commercialization, leading to substantial liabilities or cessation of activities.
• Reliance on third parties to conduct preclinical and clinical trials increases the risk of delays or inability to obtain regulatory approval or commercialize product candidates.
• Failure to regain or maintain compliance with Nasdaq Capital Market listing requirements could result in the delisting of common stock.
• A limited public market for common stock and potential for high volatility in trading price.
• The common stock may be deemed a penny stock, making investment high-risk and subject to marketability restrictions.
• Loss of key personnel or inability to recruit qualified additional employees could hinder business strategy implementation.
• Risk of claims by third parties asserting misappropriation of intellectual property.
• Exposure to employee misconduct or other improper activities, including noncompliance with regulatory standards.
• Business and operations are vulnerable to system failures, security breaches, or cyber-attacks.
• Operations are vulnerable to interruption by natural disasters, power loss, terrorist activity, and other events beyond control.
• Competition from fully integrated biotechnology and pharmaceutical companies with significantly greater resources.
• Inability to keep up with rapid technological changes in the field or compete effectively.
• Inability to obtain third-party patient reimbursement or favorable product pricing.
• Exposure to litigation that is costly to defend or pursue and uncertain in its outcome.
• Risk of liability claims for which the company may not have adequate insurance.
• Issuance of additional shares of common stock or preferred stock would dilute the interest of current stockholders and could cause the stock price to decline.
• May not have sufficient authorized shares to issue in connection with a future capital raise without stockholder approval.
• Anti-takeover provisions may limit the ability of another party to acquire the company, potentially causing the stock price to decline.
• The company does not currently intend to pay dividends on its common stock for the foreseeable future.
• Subject to ongoing regulatory burdens resulting from its public listing.
• Failure to maintain an effective system of internal control over financial reporting could adversely affect financial reporting accuracy and investor confidence.

Future Outlook

The company anticipates starting study enrollment for its GTB-5550 clinical trial in mid-2026. It expects to continue incurring significant operating losses for the foreseeable future until product candidates are fully developed and approved. The company will need to obtain additional financing to fund its anticipated level of operations, and there is no assurance that such financing will be available on acceptable terms.

Management Comments

• "We believe our TriKE and Dual Targeting TriKE platforms that activate endogenous NK cells are potentially safer than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications."
• "Our preclinical data suggests that this is explained by the TriKE dependent, CD16 directed, IL-15 proliferation of NK cells, with little effect endogenous T cells."
• "We believe our TriKEs may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies."
• "We are advancing GTB-3650 to clinical studies based on pre-clinical data showing a marked increase in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS."
• "The Company intends to monitor the closing bid price of the common stock and assess its available options to regain compliance with the Minimum Bid Price requirement and continue listing on The Nasdaq Capital Market."
• "The Company intends to continue to vigorously defend against these claims [legal proceedings]."

Industry Context

StockSavvy.ai notes that GT Biopharma operates in the highly competitive immuno-oncology (IO) market, which reached an estimated $136 billion in 2025 and is projected to exceed $151 billion by the end of 2026. The global market for solid tumor cancers alone is estimated at $362 billion. The IO pipeline includes approximately 9,000 industry-sponsored clinical trials, with over 1,200 drugs in development and over 600 in Phase 3. While checkpoint modulators remain the dominant category by revenue, cancer vaccines, particularly mRNA-based, are seeing a resurgence with over 120 active trials. GT Biopharma's focus on novel TriKE and Dual Targeting TriKE platforms leveraging NK cells positions it within a segment seeking potentially safer alternatives to T-cell immunotherapy, but it faces intense competition from larger, more resourced pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• GT Biopharma's TriKE platform aims to be potentially safer than T-cell immunotherapy due to less cytokine release syndrome (CRS) and fewer neurological complications, offering a differentiated approach compared to established T-cell therapies like Novartis' Kymriah or Gilead's Yescarta.
• The company's strategic pivot from GTB-3550 to the more potent camelid nanobody TriKE, GTB-3650, for AML and MDS, indicates an internal drive for improved efficacy, aiming to compete with existing AML treatments such as traditional chemotherapy (e.g., cytarabine and anthracycline) and newer targeted therapies from companies like Astellas (Xospata) or Novartis (Rydapt).
• GTB-5550, targeting B7-H3 in solid tumors, places GT Biopharma in a broad and highly competitive therapeutic area, facing numerous immuno-oncology agents including checkpoint inhibitors (e.g., Merck's Keytruda, Bristol-Myers Squibb's Opdivo) and other targeted therapies developed by major pharmaceutical companies.
• The overall immuno-oncology market, valued at an estimated $136 billion in 2025, highlights a significant market opportunity but also underscores the intense competition from companies with substantially greater financial, technical, and marketing resources.

Management Changes

Corporate Governance

Legal Proceedings

• **Ohri Matter**: On July 22, 2024, the Company filed an AAA Arbitration Demand against its former CFO, Manu Ohri, for breach of fiduciary duties and contract, seeking a declaratory judgment and damages. Mr. Ohri filed counterclaims on September 3, 2024. The final hearing, originally set for June 10, 2025, is postponed indefinitely, with mediation scheduled for March 31, 2026, and a final hearing in October 2026 if mediation fails. The Company believes it has recorded an appropriate accrual.
• **TWF Global Matter**: TWF Global, LLC filed a complaint on May 24, 2023, alleging failure to deliver conversion shares. This case was dismissed on November 14, 2024, after Z-One, LLC and TWF settled their dispute. However, Z-One, LLC filed a new complaint on June 25, 2025, alleging breach of a convertible note (principal $150,000) and seeking damages over $500,000. The Company's motion to dismiss this complaint was granted with prejudice on February 27, 2026.
• **Silberfein, DiPietro, and Werthman Trust Matters**: On July 8-9, 2025, Coby Silberfein, Justin DiPietro, and Phillip Werthman Trust each filed summons with notice, alleging breach of convertible notes (principal amounts of $100,000 or $150,000) from 2021 and seeking specific performance and damages in excess of $500,000 each. The Company intends to seek dismissal of these complaints and vigorously defend against the claims.

Related Party Transactions

• **Cytovance Biologics, Inc.**: Cytovance was a related party as of December 31, 2024, but not December 31, 2025. The company recognized research and development expenses of $743,000 in 2025 and $2,335,000 in 2024. Cash payments to Cytovance were $1,054,000 in 2025 and $3,857,000 in 2024. In 2025, the company issued pre-funded warrants valued at approximately $847,000 to Cytovance as partial payment of accounts payable. In 2024, common stock valued at $810,000 was issued to Cytovance for accounts payable. As of December 31, 2025, outstanding commitments to Cytovance amounted to approximately $169,000.
• **University of Minnesota**: The company has several agreements with the University of Minnesota. The 2023 Sponsored Research Agreement (amended June 18, 2025, to expire December 31, 2025) had total payments due of approximately $1.9 million, with R&D expenses of $863,000 in 2025 and $1,078,000 in 2024. The A&R 2016 Exclusive Patent License Agreement (amended May 13, 2024) includes license maintenance fees of $50,000 in 2025 and $100,000 annually thereafter, with R&D expenses of $50,000 in 2025 and $145,000 in 2024. The 2021 Exclusive License Agreement (specific to B7H3 targeted TriKE) has annual license maintenance fees of $5,000, with R&D expenses of $5,000 in 2025. The 2024 GTB-3650 Clinical Trial Agreement has a budget of up to $2 million over three years, with R&D expenses of $750,000 in 2025 and $190,000 in 2024, and commitments of approximately $1.1 million as of December 31, 2025.
• **PDPC Advisors Inc.**: On June 30, 2025, the company entered into an Advisory Agreement with PDPC Advisors Inc., involving cash payments of $100,000 and the issuance of a pre-funded warrant with a fair value of $537,000. PDPC is considered a related party because its CEO has voting and investment control over an entity with beneficial ownership exceeding 5% of the company's common stock.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises, the risk of delisting from Nasdaq due to minimum bid price non-compliance, and potential volatility in stock price. The restatement of financial statements and identified material weakness in internal controls could erode investor confidence.
• **Employees and Consultants**: The company operates with one full-time employee and numerous consultants, making it highly dependent on key personnel. The loss of such personnel or inability to recruit qualified individuals poses a significant risk to operations. Employee misconduct could lead to regulatory sanctions and reputational damage.
• **Patients**: Delays or failures in clinical trials for product candidates (GTB-3650, GTB-5550, GTB-7550) would delay the availability of potential new treatments for serious conditions like AML, MDS, solid tumors, and autoimmune disorders.
• **Creditors**: The company's substantial operating losses and explicit 'going concern' doubt indicate increased financial risk for creditors.
• **Suppliers and Manufacturers (e.g., Cytovance)**: The company's reliance on third-party contract manufacturing means that disruptions, compliance issues, or capacity limitations could negatively impact product supply and development timelines.
• **Regulatory Bodies (FDA, Nasdaq)**: The company is subject to extensive regulation, and non-compliance (e.g., Nasdaq listing rules, financial reporting standards) can lead to penalties, delisting, or delays in product approvals.

Next Steps

• Continue study enrollment and data collection for the GTB-3650 clinical trial.
• Anticipate starting study enrollment for the GTB-5550 clinical trial in mid-2026.
• Explore and assess potential manufacturers for GTB-7550.
• Monitor the common stock bid price and assess available options to regain Nasdaq compliance by May 19, 2026.
• Participate in mediation for the Ohri legal matter scheduled for March 31, 2026, with a final hearing in October 2026 if mediation is unsuccessful.
• Vigorously defend against the Silberfein, DiPietro, and Werthman Trust legal claims.
• Implement additional internal controls, including engaging an accounting consultant for complex financial transactions, to remediate the identified material weakness in internal controls.
• Potentially utilize the Committed Equity Facility to raise additional capital to fund operations.

Key Dates

Recommendation

The company's financial health is severely compromised, evidenced by a substantial increase in net loss, explicit 'going concern' doubt from both management and auditors, and a Nasdaq non-compliance notice for its share price. While there is some clinical progress with IND clearances, the early stage of development, intense competition in the immuno-oncology market, and ongoing significant capital requirements in a high-risk industry make the investment highly speculative. The material weakness in internal controls and financial restatement further erode confidence. Given these significant financial and operational challenges, a seasoned investor would likely recommend selling to mitigate risk.

Keywords

Immuno-oncology, TriKE, Natural Killer Cells, Biopharmaceutical, Clinical Stage, AML, MDS, Solid Tumors, Autoimmune Disorders, FDA IND, Nasdaq Listing, Going Concern, Capital Raise, GTB-3650, GTB-5550, GTB-7550, Camelid Nanobody, Financial Restatement